Product Information
- 4-(Cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-5-pyrimidinecarboxamide,
- 5-Pyrimidinecarboxamide, 4-(cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-
- PRT 062070
- PRT 2017
- Cerdulatinib
- 4-(Cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-5-pyrimidinecarboxamide
Applications Cerdulatinib (PRT2070), acts as a novel oral and dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Preferentially selects for JAK inhibitors (JAK1 and JAK3 primarily), preventing cytokine mediated signaling and functional responses varying cell types. Potential anti-cancer agent.
References Coffey, G. et al.: J. Pharmacol. Exp. Ther., 351, 538 (2014);
Chemical properties
Technical inquiry about: TR-C273000 Cerdulatinib (PRT2070)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.